Marshall Wace’s Trillium Therapeutics Inc. TRIL Stock Holding History

Marshall Wace’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-160,062	Closed	-$2.81M	–	4554
2021 Q3	$2.81M	Sell	160,062 -256,862	-62%	-$3M	0.01%	1307
2021 Q2	$4.04M	Buy	416,924 +19,979	+5%	+$188K	0.02%	966
2021 Q1	$4.26M	Buy	396,945 +372,463	+1,521%	+$4.61M	0.02%	924
2020 Q4	$360K	Buy	+24,482	New	+$353K	﹤0.01%	1602
2019 Q2	–	Sell	-110,282	Closed	-$73K	–	2014
2019 Q1	$73K	Buy	+110,282	New	+$135K	﹤0.01%	1484

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Marshall Wace's TRIL Position: Q4 2021 in Review

Marshall Wace sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 160,062 shares — an estimated $2.81M sold.

Marshall Wace first reported a position in TRIL in Q1 2019 and held it in 5 quarters. The position peaked at $4.26M in Q1 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Marshall Wace reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Marshall Wace sold 160,062 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $2.81M.
Marshall Wace first reported a position in Trillium Therapeutics Inc. in Q1 2019 and held it in 5 quarters.
Marshall Wace's Trillium Therapeutics Inc. position peaked at $4.26M in Q1 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Marshall Wace's 13F filing for Q4 2021, filed 14 Feb 2022.